Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Sofen H, et al. Among authors: bissonnette r. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36816342 Free PMC article.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators. Kimball AB, et al. Among authors: bissonnette r. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. doi: 10.1111/jdv.12046. Epub 2012 Dec 20. J Eur Acad Dermatol Venereol. 2013. PMID: 23279003 Clinical Trial.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group. Ryan C, et al. Among authors: bissonnette r. Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22. Br J Dermatol. 2018. PMID: 29747232 Clinical Trial.
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Guttman-Yassky E, et al. Among authors: bissonnette r. J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5. J Allergy Clin Immunol. 2019. PMID: 30194992 Free article. Clinical Trial.
Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement.
Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ, Guttman-Yassky E. Leshem YA, et al. Among authors: bissonnette r. J Eur Acad Dermatol Venereol. 2019 May;33(5):807-815. doi: 10.1111/jdv.15480. Epub 2019 Mar 12. J Eur Acad Dermatol Venereol. 2019. PMID: 30859656 Free PMC article.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E. Bissonnette R, et al. Br J Dermatol. 2019 Oct;181(4):733-742. doi: 10.1111/bjd.17932. Epub 2019 May 6. Br J Dermatol. 2019. PMID: 30919407 Free PMC article. Clinical Trial.
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.
Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P, Ardeleanu M, Hultsch T, Guttman-Yassky E, Bissonnette R, Silverberg JI, Krueger J, Menter A, Graham NMH, Pirozzi G, Hamilton JD, Gallo RL. Callewaert C, et al. Among authors: bissonnette r. J Invest Dermatol. 2020 Jan;140(1):191-202.e7. doi: 10.1016/j.jid.2019.05.024. Epub 2019 Jun 25. J Invest Dermatol. 2020. PMID: 31252032 Free PMC article. Clinical Trial.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Among authors: bissonnette r. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838
324 results